AVID200 improves platelet counts among patients with advanced myelofibrosis
John Mascarenhas, MD, discusses his research finding that a novel therapy for the bone marrow cancer myelofibrosis is safe, well-tolerated and is associated with modest improvements in patients in a phase 1b clinical trial.
